Absci (ABSI) Stock Price, News & Analysis

Company Overview

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework. By integrating AI-driven protein design with advanced screening processes, the company seeks to rapidly advance promising biologic candidates from concept through lead optimization. Absci’s platform supports research in areas such as oncology, immunology and metabolic disease, providing partners with drug-like protein candidates and data insights that can de-risk preclinical development.

Founded in 2018 and headquartered in Seattle, Washington, Absci maintains collaborative relationships with multiple global pharmaceutical organizations and operates additional research facilities in the United States. The company’s leadership team brings together experts in protein engineering, data science and drug development, aiming to transform biologics discovery through technological innovation. As Absci continues to expand its pipeline partnerships and platform capabilities, it remains focused on delivering scalable solutions for the next generation of protein therapeutics.

Key Stats

• Today's Range: $7.51 to $8.26
• 50-Day Range: $4.64 to $11.62
• 52-Week Range: $2.24 to $12.06
• Volume: 2.59 million shs
• Average Volume: 4.20 million shs
• Market Capitalization: $1.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.43
• Consensus Rating: Moderate Buy

Absci Stock Analysis - MarketRank™

Absci scored higher than 72% of companies evaluated by MarketBeat, and ranked 203rd out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Absci has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Absci has a consensus price target of $13.43, representing about 77.6% upside from its current price of $7.56.

Amount of Analyst Coverage

Absci has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Absci are expected to grow in the coming year, from ($0.71) to ($0.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Absci is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Absci is -9.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Absci has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.63% of the float of Absci has been sold short.

Short Interest Ratio / Days to Cover

Absci has a short interest ratio ("days to cover") of 7.93.

Change versus previous month

Short interest in Absci has recently decreased by 3.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Absci does not currently pay a dividend.

Dividend Growth

Absci does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.25

News Sentiment

Absci has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Absci this week, compared to 5 articles on an average week.

Search Interest

26 people have searched for ABSI on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.

MarketBeat Follows

10 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Absci insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.52% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/26/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ABSI
• CIK: 1672688
• Web: www.absci.com
• Phone: 360-949-1041
• Fax: N/A
• Employees: 210
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Absci: $13.43
• High Price Target: $17.00
• Low Price Target: $10.00
• Potential Upside/Downside: +77.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$115.18 million
• Net Margins: -6,450.76%
• Pretax Margin: -6,445.81%
• Return on Equity: -66.32%
• Return on Assets: -57.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.59
• Quick Ratio: 6.59

Sales & Book Value

• Annual Sales: $2.80 million
• Price / Sales: 420.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: 6.00

Miscellaneous

• Outstanding Shares: 155,900,000
• Free Float: 139,504,000
• Market Cap: $1.18 billion
• Optionable: Optionable
• Beta: 2.32